Imidazopyrazinones (IPYs) : Non-Quinolone Bacterial Topoisomerase Inhibitors Showing Partial Cross-Resistance with Quinolones
In our quest for new antibiotics able to address the growing threat of multidrug resistant infections caused by Gram-negative bacteria, we have investigated an unprecedented series of non-quinolone bacterial topoisomerase inhibitors from the Sanofi patrimony, named IPYs for imidazopyrazinones, as part of the Innovative Medicines Initiative (IMI) European Gram Negative Antibacterial Engine (ENABLE) organization. Hybridization of these historical compounds with the quinazolinediones, a known series of topoisomerase inhibitors, led us to a novel series of tricyclic IPYs that demonstrated potential for broad spectrum activity, in vivo efficacy, and a good developability profile, although later profiling revealed a genotoxicity risk. Resistance studies revealed partial cross-resistance with fluoroquinolones (FQs) suggesting that IPYs bind to the same region of bacterial topoisomerases as FQs and interact with at least some of the keys residues involved in FQ binding.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Journal of medicinal chemistry - 61(2018), 8 vom: 26. Apr., Seite 3565-3581 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jeannot, Frédéric [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 23.04.2019 Date Revised 29.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.jmedchem.7b01892 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM282477128 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM282477128 | ||
| 003 | DE-627 | ||
| 005 | 20231225034017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.jmedchem.7b01892 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0941.xml |
| 035 | |a (DE-627)NLM282477128 | ||
| 035 | |a (NLM)29596745 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jeannot, Frédéric |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Imidazopyrazinones (IPYs) |b Non-Quinolone Bacterial Topoisomerase Inhibitors Showing Partial Cross-Resistance with Quinolones |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2019 | ||
| 500 | |a Date Revised 29.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In our quest for new antibiotics able to address the growing threat of multidrug resistant infections caused by Gram-negative bacteria, we have investigated an unprecedented series of non-quinolone bacterial topoisomerase inhibitors from the Sanofi patrimony, named IPYs for imidazopyrazinones, as part of the Innovative Medicines Initiative (IMI) European Gram Negative Antibacterial Engine (ENABLE) organization. Hybridization of these historical compounds with the quinazolinediones, a known series of topoisomerase inhibitors, led us to a novel series of tricyclic IPYs that demonstrated potential for broad spectrum activity, in vivo efficacy, and a good developability profile, although later profiling revealed a genotoxicity risk. Resistance studies revealed partial cross-resistance with fluoroquinolones (FQs) suggesting that IPYs bind to the same region of bacterial topoisomerases as FQs and interact with at least some of the keys residues involved in FQ binding | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a Quinazolinones |2 NLM | |
| 650 | 7 | |a Topoisomerase Inhibitors |2 NLM | |
| 700 | 1 | |a Taillier, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Despeyroux, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Renard, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Rey, Astrid |e verfasserin |4 aut | |
| 700 | 1 | |a Mourez, Michaël |e verfasserin |4 aut | |
| 700 | 1 | |a Poeverlein, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Khichane, Imène |e verfasserin |4 aut | |
| 700 | 1 | |a Perrin, Marc-Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Versluys, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Stavenger, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jianzhong |e verfasserin |4 aut | |
| 700 | 1 | |a Germe, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Maxwell, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Sha |e verfasserin |4 aut | |
| 700 | 1 | |a Huseby, Douglas L |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Diarmaid |e verfasserin |4 aut | |
| 700 | 1 | |a Bacqué, Eric |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medicinal chemistry |d 1963 |g 61(2018), 8 vom: 26. Apr., Seite 3565-3581 |w (DE-627)NLM000006602 |x 1520-4804 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2018 |g number:8 |g day:26 |g month:04 |g pages:3565-3581 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.jmedchem.7b01892 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2018 |e 8 |b 26 |c 04 |h 3565-3581 | ||